Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has received rights for the research, development and commercialization of Boehringer Ingelheim's non-catalytic site integrase inhibitors (NCINIs) - BI 224436 to treat HIV.
Subscribe to our email newsletter
NCINIs inhibits HIV integrase by binding to a novel site and target the key component of the HIV virus.
BI 224436 has been evaluated in a Phase 1a dose-escalation study to assess bioavailability and pharmacokinetics in healthy volunteers.
Gilead will pay Boehringer Ingelheim an upfront payment, as per the terms of the agreement.
Boehringer Ingelheim could receive additional payments based upon the achievement of certain development, regulatory and commercial milestones, as well as royalties on future net sales.
Gilead Sciences CSO and Research and Development executive vice president Norbert Bischofberger said they are looking forward to progress BI 224436 or other compounds further into clinical development.
Boehringer Ingelheim Medicine corporate senior vice president Klaus Dugi said while Gilead will drive the integrase inhibitors in HIV into clinical development, they will focus their development efforts on further compounds of their virology pipeline, particularly their portfolio in hepatitis C.